February 2010
MondayMorning;2/1/2010, Vol. 18 Issue 4, p4
The article offers updates related to research and technology in the U.S. A prostate cancer vaccine with smallpox virus helped cancer patients who are untreatable to live longer. Keryx Biopharmaceuticals Inc. affirms the effectiveness of its drug KRX-0401 in the survival of patients heavily pre-treated with advanced metastatic colon cancer. AmerisourceBergen Corp. raises profits and revenue due to new business, launching of generic drug, and cost controls.


Related Articles

  • Sipuleucel-T Suspension for Intravenous Infusion (Provenge). Elliott, William T.; Chan, James // Internal Medicine Alert;6/15/2010, Vol. 32 Issue 11, p85 

    The article provides information on Sipuleucel-T vaccine, a cellular immunotherapy suggested to treat prostate cancer.

  • Supply chain, new drug therapies drive AmeriSource Bergen 1Q sales.  // Drug Store News;2/17/2003, Vol. 25 Issue 2, p32 

    Reports on the net earnings of drug wholesaler AmerisourceBergen in the U.S. Growth of the company revenue; Increase in pharmaceutical distribution; Factors contributing for the increase in the profit.

  • Profits expected to rise 8% to 12% in fiscal year.  // Chain Drug Review;7/16/2012, Vol. 34 Issue 12, p52 

    The article reports that profits earned by AmerisourceBergen Corp. in fiscal 2012 are expected to increase 8-12%.

  • Financial results top expectations in second quarter.  // Chain Drug Review;6/7/2010, Vol. 32 Issue 10, p61 

    The article reports on the increase in the earnings of AmerisourceBergen Corp. for the second quarter of 2010 which was facilitated by the sales of generic drugs and cost controls in the U.S.

  • AmerisourceBergen earnings rise 6.1% in quarter.  // Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p16 

    The article reports on the corporate profit of AmerisourceBergen Corp. which increased by 6.1 percent to 160.5 million dollars in December 2010 in the U.S.

  • Setting high expectations for performance. Tosh, Mark // Drug Store News;12/17/2001, Vol. 23 Issue 19, p46 

    Reports on the financial performance of AmerisourceBergin in 2001. Operating revenue posted by the company in the fourth quarter that ended September 30, 2001; Net income and earnings per share of the company for the year; Trading status of the company's stocks at the New York Stock Exchange.

  • Earnings advance 30.4% at AmerisourceBergen.  // Chain Drug Review;9/13/2010, Vol. 32 Issue 15, p16 

    The article reports on the 30.4% earning increase of AmerisourceBergen Corp. from its continuing operations on a 6.6% revenue gain in Valley Forge, Pennsylvania.

  • Outlook for balance of fiscal year raised.  // Chain Drug Review;9/13/2010, Vol. 32 Issue 15, p16 

    The article reports that Amerisource-Bergen Corp. has raised its earnings projection for 2010 to a range of 2.16 dollars to 2.20 dollars per diluted share in Valley Forge, Pennsylvania.

  • First cancer vaccine approved for use in people.  // New Scientist;5/8/2010, Vol. 206 Issue 2759, p5 

    The article discusses a prostate cancer vaccine called Provenge that has been approved by the U.S. Food and Drug Administration (FDA) for use in humans.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics